A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
. They are calculated for the Gaussian distribution of asperities, which have been shown to be unrealistic for engineering surface but can be assumed where friction, load carrying capacity or real contact area results are not critical to the analysis.
Through the use of a piston in a cylinder this pump creates pressure by using a one way valve and a piston that is controlled by the handle. The Bicycle pump is a vertical hand pump that is used to inflate bicycle tires. these pumps are very common and can be used to inflate many things with the use of an adapter. Diaphragm Pumps
== Medical uses == Labetalol is effective in the management of hypertensive emergencies, postoperative hypertension, pheochromocytoma-associated hypertension, and rebound hypertension from beta blocker withdrawal. It has a particular indication in the treatment of pregnancy-induced hypertension which is commonly associated with pre-eclampsia. It is also used as an alternative in the treatment of severe hypertension. Labetalol is useful in the treatment of acute cardiovascular toxicity (e.g. in overdose) caused by sympathomimetics like amphetamine, methamphetamine, cocaine, ephedrine, and pseudoephedrine. Other beta blockers are also used. However, the controversial yet possible phenomenon of "unopposed α-stimulation" with administration of selective beta blockers to block non-selective sympathomimetics potentially makes dual alpha-1 and beta blockers like labetalol and carvedilol more favorable for such purposes. The rate of unopposed α-stimulation with selective beta blockers has been reported to be 0.4%, whereas no cases of unopposed α-stimulation have been reported with dual alpha and beta blockers like labetalol.
Sources: en.wikipedia.org
While originally thought to be a serine protease, OmpT is better characterized as an aspartyl protease because of its cleavage mechanism. The substrate of OmpT binds to negatively charged aspartate and glutamate residues, so the active site of the protease is anionic. This causes OmpT to selectively cleave peptides between two basic (positively charged) residues. The active site of OmpT resembles that of other omptins, and is characterized by conserved residues at Asp84, Asp86, Asp206, and His208. The most common bond cleavage by OmpT is between two arginine residues because their positive charge can favorably interact with the negatively charged species at the active site during substrate binding. Because of the specificity of the active site, OmpT does not act on peptides with a negatively charged residue adjacent to the scissile bond. Also, OmpT is specifically identified an endopeptidase because it does not cleave peptides at the N- or C-terminus, but only between nonterminal amino acids. The peptide bond cleavage occurs via the nucleophilic attack of water at the carbonyl between two adjacent amino acid residues. Water enters the protease from the intracellular surface and is stabilized by Asp83 and His212. During the proton transfer associated with the peptide cleavage, the negatively charged aspartate residue stabilizes the positively charged histidine. Once docked in this position, water is positioned to attack the peptide in the active site. The cleavage of peptide bonds by OmpT is also dependent on the presence of bound lipopolysaccharide (LPS).
Foliate papillae (from Latin foliātus 'leafy') are short vertical folds and are present on each side of the tongue. They are located on the sides at the back of the tongue, just in front of the palatoglossal arch of the fauces. There are four or five vertical folds, and their size and shape is variable. The foliate papillae appear as a series of red colored, leaf–like ridges of mucosa. They are covered with epithelium, lack keratin and so are softer, and bear many taste buds. They are usually bilaterally symmetrical. Sometimes they appear small and inconspicuous, and at other times they are prominent. Because their location is a high risk site for oral cancer, and their tendency to occasionally swell, they may be mistaken as tumors or inflammatory disease. Taste buds, the receptors of the gustatory sense, are scattered over the mucous membrane of their surface. Serous glands drain into the folds and clean the taste buds. Lingual tonsils are found immediately behind the foliate papillae and, when hyperplastic, cause a prominence of the papillae.
== See also == Bioluminescence imaging Gene expression Gene knock-in Gene regulatory network GUS reporter system Molecular cloning Promoter (genetics) Selectable marker Synthetic biology Transcription factor Transfection
=== Composition and selectivity === Condensate components are usually divided into scaffolds, which drive phase separation, and clients, which do not phase separate on their own but can still be recruited into the dense phase. Client recruitment depends on the number of available binding sites as well as the valency and affinity of the client, so changes in scaffold stoichiometry can alter the composition of the condensate. Partitioning is also influenced by physical factors that are distinct from specific binding. Because condensates consist of dense networks of intrinsically disordered regions (IDRs), inserting a molecule restricts the conformational freedom of the surrounding chains, resulting in an entropic penalty that increases with particle size. Calculations combined with coarse-grained modelling show that the free energy of insertion increases with both IDR density and particle size, and becomes dependent on particle surface area once the particle is larger than the network mesh size. At typical IDR concentrations, particles as small as 4 nm in diameter can be almost entirely excluded, with approximately 97% exclusion in the absence of favourable interactions with condensate components.
Sources: en.wikipedia.org
== Advantages and disadvantages == The major advantage of CYTOF is the ability to investigate a larger number of parameters per panel than other cytometry methods. This allows a greater understanding of complex and heterogeneous cell populations, without the need for many complex and overlapping panels. Panels can include up to 45 antibodies, as opposed to the 10 that can be done in conventional flow cytometry but require great expertise to design. However, development of spectral flow cytometry has closed the gap between flow and mass cytometry in terms of the maximum number of antibodies that can be used. More antibodies per panel saves on time, allows understanding of a larger picture, and requires fewer numbers of cells per experiment, which is particularly advantageous when samples are limited such as with tumour studies. The use of the heavy metal isotopes also lowers background when compared to using fluorescent antibodies. Some cell types, such as myeloid cells, have high rates of autofluorescence that create a lot of background noise in flow cytometry. However, the rare heavy metal isotopes used are not present in biological systems, therefore there is very little or no background seen, and overall sensitivity is increased. The detection overlap between the different heavy metals is also very low compared to the overlap seen in fluorescent cytometry, which makes it much simpler to design a panel of many markers. Fluorescent dyes are subject to photobleaching, requiring the entire process to happen within a few hours after staining.
{\displaystyle {\begin{aligned}{\frac {dS}{dt}}&=\Lambda -{\frac {\beta SI}{N}}-\mu S+\gamma I\\[6pt]{\frac {dE}{dt}}&={\frac {\beta SI}{N}}-(\epsilon +\mu )E\\[6pt]{\frac {dI}{dt}}&=\epsilon E-(\gamma +\mu )I\end{aligned}}}
=== Neuropad === Neuropad utilizes an adhesive pad with a cobalt (II) salt indicator that changes color from blue to pink in the presence of moisture due to the hydration of cobalt ions. One pad is applied to the plantar surface of each foot in between the 1st and 2nd metatarsal heads. The pad is kept on each foot for ten minutes and the final color is recorded. A full change in color from blue to pink is considered a normal sweat response, while an absent or incomplete color change is considered abnormal. The strengths of Neuropad are its high sensitivity, cost-effectiveness, and its potential as an at-home test. However, Neuropad has lower specificity, is not recommended for children and patients over the age of 70, and is sensitive to certain medications.
However, it was soon realized that submarines could approach enemy coastlines undetected and decrease the warning time (the time between detection of the missile launch and the impact of the missile) from as much as half an hour to possibly under three minutes. This effect was especially significant to the United States, Britain and China, whose capitals of Washington D.C., London, and Beijing all lay within 100 miles (160 km) of their coasts. Moscow was much more secure from this type of threat, due to its considerable distance from the sea. This greatly increased the credibility of a "surprise first strike" by one faction and (theoretically) made it possible to knock out or disrupt the chain of command of a target nation before any counterstrike could be ordered (known as a "decapitation strike"). It strengthened the notion that a nuclear war could possibly be "won", resulting not only in greatly increased tensions and increasing calls for fail-deadly control systems, but also in a dramatic increase in military spending. The submarines and their missile systems were very expensive, and one fully equipped nuclear-powered and nuclear-armed missile submarine could cost more than the entire GNP of a developing country. It was also calculated, however, that the greatest cost came in the development of both sea- and land-based anti-submarine defenses and in improving and strengthening the "chain of command", and as a result, military spending skyrocketed. South Africa developed a nuclear weapon capability during the 1970s and early 1980s.
=== Analogues and derivatives === Analogues of 2C-B include 2C-I, 2C-C, DOB, 4C-B, 2C-B-FLY, and 25B-NBOMe, among others. DOB and 4C-B are α-alkyl derivatives of 2C-B, specifically the amphetamine (α-methyl) and phenylisobutylamine (α-ethyl) derivatives, respectively. β-Substituted derivatives of 2C-B such as BOB (β-methoxy-2C-B), BOH-2C-B (β-hydroxy-2C-B), βk-2C-B (β-keto-2C-B), and β-methyl-2C-B (BMB) have been described. βk-2C-B shows dramatically reduced potency and efficacy as a serotonin 5-HT2A receptor agonist compared to 2C-B. A variety of N-substituted derivatives of 2C-B have been tested, including N-methyl-2C-B, N,N-dimethyl-2C-B, N-ethyl-2C-B, and N-benzyl-2C-B. Most simple alkyl derivatives were considerably less potent than 2C-B, with N-ethyl-2C-B for instance having a 40 times lower affinity for the serotonin 5-HT2A receptor. The N-benzyl derivative however was found to have higher affinity than 2C-B itself, with N-(4-bromobenzyl)-2C-B binding even more tightly. This initial research did not include functional assays of activity, but later led to the development of potent substituted N-benzyl derivatives such as 25B-NBOMe, and 25B-NBOH. Another N-substituted derivative, 2C-B-AN, is an N-benzylphenethylamine-like prodrug of 2C-B. 2C-DB (6-bromo-2C-B) is a ring-substituted derivative of 2C-B. TWEETIO derivatives of 2C-B, in which one or both of the methoxy groups of 2C-B are extended to ethoxy groups, exist as well, such as 2CB-2-EtO.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.